↓ Skip to main content

Dove Medical Press

Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD

Overview of attention for article published in Drug Design, Development and Therapy, July 2010
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (71st percentile)

Mentioned by

policy
1 policy source
patent
1 patent

Citations

dimensions_citation
120 Dimensions

Readers on

mendeley
97 Mendeley
Title
Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD
Published in
Drug Design, Development and Therapy, July 2010
DOI 10.2147/dddt.s7667
Pubmed ID
Authors

Mark A Giembycz, Stephen K Field

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 97 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Germany 1 1%
Unknown 96 99%

Demographic breakdown

Readers by professional status Count As %
Student > Master 16 16%
Researcher 14 14%
Student > Bachelor 11 11%
Student > Ph. D. Student 10 10%
Other 7 7%
Other 22 23%
Unknown 17 18%
Readers by discipline Count As %
Medicine and Dentistry 33 34%
Agricultural and Biological Sciences 13 13%
Pharmacology, Toxicology and Pharmaceutical Science 8 8%
Biochemistry, Genetics and Molecular Biology 7 7%
Chemistry 6 6%
Other 12 12%
Unknown 18 19%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 April 2018.
All research outputs
#5,452,627
of 25,394,764 outputs
Outputs from Drug Design, Development and Therapy
#372
of 2,270 outputs
Outputs of similar age
#22,348
of 103,899 outputs
Outputs of similar age from Drug Design, Development and Therapy
#2
of 4 outputs
Altmetric has tracked 25,394,764 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,270 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one has done well, scoring higher than 82% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 103,899 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.